Acurx Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Acurx Pharmaceuticals, Inc. (ACXP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.94 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-13
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $12.40, a 369.70% increase year-over-year.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $2.64, a 6.05% decline year-over-year.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $2.81, a 25.86% decline year-over-year.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $3.79.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $12.33, a 76.20% decline from fiscal 2024.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $51.80, a 1783.64% increase from fiscal 2023.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $2.75, a 22.32% decline from fiscal 2022.
- Acurx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $3.54, a 25.00% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.94 10-Q · filed 2026-08-13 | |||||||
| 2025-12-31 | $12.33 10-K · filed 2026-03-12 | |||||||
| 2025-09-30 | $12.33 10-Q · filed 2025-11-12 | |||||||
| 2025-06-30 | $12.33 10-Q · filed 2026-08-13 | |||||||
| 2025-03-31 | $12.40 10-Q · filed 2026-05-11 | $0.62 10-Q · filed 2025-05-12 | ||||||
| 2024-12-31 | $51.80 10-K · filed 2026-03-12 | $2.59 10-K · filed 2025-03-17 | ||||||
| 2024-09-30 | $51.80 10-Q · filed 2025-11-12 | $2.59 10-Q · filed 2024-11-12 | ||||||
| 2024-06-30 | $51.80 10-Q · filed 2025-08-11 | $2.59 10-Q · filed 2024-08-08 | ||||||
| 2024-03-31 | $2.64 10-Q · filed 2025-05-12 | |||||||
| 2023-12-31 | $2.75 10-K · filed 2025-03-17 | |||||||
| 2023-09-30 | $2.75 10-Q · filed 2024-11-12 | |||||||
| 2023-06-30 | $2.75 10-Q · filed 2024-08-08 | |||||||
| 2023-03-31 | $2.81 10-Q · filed 2024-05-14 | |||||||
| 2022-12-31 | $3.54 10-K · filed 2024-03-15 | |||||||
| 2022-09-30 | $3.54 10-Q · filed 2022-11-10 | |||||||
| 2022-06-30 | $3.54 10-Q · filed 2022-08-12 | |||||||
| 2022-03-31 | $3.79 10-Q · filed 2022-05-10 | |||||||
| 2021-12-31 | $4.72 10-K · filed 2022-03-16 | |||||||
| 2021-09-30 | $4.72 10-Q · filed 2021-11-12 | |||||||
| 2021-06-30 | $4.75 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |